These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 12233260)
1. [Monoamine oxidase inhibitors: prospects for the use in clinical practice]. Evtushenko SK; Lutskiĭ IS; Efimenko VN; Kazarian NE Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(8):53-60. PubMed ID: 12233260 [No Abstract] [Full Text] [Related]
2. MAO-B inhibitors for the treatment of Parkinson's disease. Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138 [No Abstract] [Full Text] [Related]
6. MAO-B inhibitor know-how: back to the pharm. Lewitt PA Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057 [No Abstract] [Full Text] [Related]
7. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Berry MD; Juorio AV; Paterson IA Prog Neurobiol; 1994 Oct; 44(2):141-61. PubMed ID: 7831475 [No Abstract] [Full Text] [Related]
13. MAO type B inhibitors as adjunct to L-dopa therapy. Youdim MB; Finberg JP Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383 [No Abstract] [Full Text] [Related]
14. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Youdim MB; Riederer PF Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584 [No Abstract] [Full Text] [Related]
15. Neuroprotection for Parkinson's disease: prospects and promises. Olanow CW; Schapira AH; Agid Y Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093 [No Abstract] [Full Text] [Related]
16. Neuroprotection by selegiline and other MAO inhibitors. Stern G J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613 [TBL] [Abstract][Full Text] [Related]